Abstract
Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID
Author(s): Riepl Mike, Kaiser Joe
Issue: Jul/Aug 2023 - Volume 27, Number 4
Page(s): 284-293
Abstract
People infected by severe acute respiratory coronavirus 2 (SARS-CoV-2) risk the development of not only acute coronavirus- disease–2019 (COVID-19) — the signs and symptoms of which range from none to severe illness that requires intensive treatment — but also long COVID (i.e., chronic COVID), a cyclical, progressive, multiphasic illness characterized by myriad debilitating conditions that persist long term. In some patients, those sequelae result in psychiatric disorders that can lead to suicide or other forms of self-harm, incidences of which have increased exponentially since before the COVID pandemic. It has been suggested that long COVID develops in an estimated 10% to 35% of people diagnosed as having COVID-19. Because the success of therapy for either form of COVID can be complicated by each patient’s pharmacogenomic profile, personal treatment preferences, medical needs, and/or dosing requirements, we have found that in some people so afflicted, manufactured medications are ineffective or intolerable, and that for those individuals, a customized compound often provides relief and promotes recovery. The primary focus of this article is long COVID. The pathogenesis of that disease is reviewed, therapies for the signs and symptoms it engenders are examined, and 2 compounded formulations effective in treating both acute and chronic COVID-19 are presented.
Related Keywords
- severe acute respiratory coronavirus 2
- SARS-CoV-2
- acute coronavirus disease 2019
- COVID-19
- long COVID
- chronic COVID
- suicidal thinking
- self harm
- suffering
- burden of disease
- quality of life
- inflammation
- cytokine release syndrome
- cytokine storm
- immune system dysregulation
- microclot formation
- tissue perfusion
- ischemia
- fatigue
- dyspnea
- post exertional malaise
- brain fog
- arthralgias
- paresthesias
- dysautonomia
- Toll-like receptor 4
- TLR4 antagonists
- statins
- low-dose naltrexone
- formulations
- theophylline nasal spray
- opioid receptor blockade
- naltrexone hydrochloride troche
Related Categories
- FORMULATIONS
- MENTAL HEALTH
- ALLERGY/IMMUNOLOGY/INFLAMMATION
- INFECTIOUS DISEASE
Related Articles from IJPC
Issue/Page View/Buy |
Title/Author (Click for Abstract / Details / Purchase) |
---|---|
Jul/Aug 2023
Pg. 284-293
|
Author(s):
Riepl Mike, Kaiser Joe
|
Jan/Feb 2023
Pg. 12-21
|
Author(s):
Riepl Mike
|
May/Jun 2023
Pg. 192-200
|
Author(s):
Riepl Mike, Kaiser Joe
|
Sep/Oct 2023
Pg. 368-380
|
Author(s):
Riepl Mike, Kaiser Joe
|
Mar/Apr 2023
Pg. 98-107
|
Author(s):
Riepl Mike
|
Jul/Aug 2020
Pg. 287-295
|
Author(s):
McElhiney Linda F
|
Jul/Aug 2020
Pg. 268
|
Author(s):
Allen Loyd V Jr
|
Sep/Oct 2020
Pg. 358-364
|
|
Mar/Apr 2021
Pg. 109-113
|
|
Jul/Aug 2003
Pg. 288-291
|
Author(s):
Glasnapp Andrew
|
Jul/Aug 2020
Pg. 316
|
Author(s):
Allen Loyd V Jr
|
Jul/Aug 2020
Pg. 310
|
Author(s):
Stockton Shelly J
|
May/Jun 2003
Pg. 188-191
|
Author(s):
Davidson Gigi S
|
Jul/Aug 2003
Pg. 266-270
|
Author(s):
Kuntz Rachael
|
Sep/Oct 2002
Pg. 338-343
|
Author(s):
Lascelles B Duncan
|
Jul/Aug 2021
Pg. 296-297
|
Author(s):
Brunner Scott
|
Sep/Oct 2022
Pg. 432-435
|
Author(s):
Marianni Bruna, Polonini Hudson
|
Jul/Aug 2021
Pg. 268
|
Author(s):
Allen Loyd V Jr
|
May/Jun 2020
Pg. 194-197
|
|
Sep/Oct 2021
Pg. 386-387
|
Author(s):
Brunner Scott
|